Biobank studies review human biological samples and medical information about patients. The results help to accelerate research studies to find new treatments for diseases such as lymphoma.
If you donate a blood sample, or tissue from a biopsy, it will be kept in a freezer, sometimes for long periods of time. It is usual for patients donating a sample to also complete questionnaires as the samples are more valuable if researches know about the person it comes from.
Observational studies If you are involved in an observational study you may be asked to complete questionnaires about your care and treatment experiences. The information gathered is valuable for ongoing research, it enables researchers to spot trends and important factors which may not have been found otherwise.
Below is a list of our current non-drug clinical trials:
The HORIZONS study is suitable for patients with a new diagnosis of diffuse large B cell lymphoma (DLBCL).
The aim of this study is to find out about how a cancer diagnosis and treatment affect a person’s health and wellbeing and participants will be asked to complete questionnaires. Please click here for more information.
The PROCLIPI study involves patients with all stages of mycosis fungoides (primary cutaneous T cell lymphoma) and Sézary syndrome. All patients must have been diagnosed for no more than 6 months.
We don’t know why, but in some patients (1 in 5) the skin lymphoma progresses more rapidly. The purpose of this study is to find out why some patients progress more quickly than others. This will allow us to develop a prognostic index which in turn will provide patients and their doctors with more information about their disease.
We are collecting data on patients including information on skin involvement, stage of disease, blood tests, biopsy tests, treatment and quality of life. We may perform future research on blood and skin samples but no additional tests are needed.
The MaPLe study is suitable for patients with suspected or confirmed diffuse large B-cell lymphoma or grade 3b follicular lymphoma. Patients involved in this study can be newly diagnosed or have already received treatment but it has come back.
If you give your consent to be involved in this study, we will seek your permission to perform additional tests on the biopsy that was taken to diagnose your lymphoma. These tests look at the genes in your lymphoma, the process is called molecular profiling. The aim is to find out whether you would be suitable for other treatments with drugs which target gene changes in lymphoma cells.
Molecular profiling may take several weeks to perform and we start the process whilst you undergo further investigations for your lymphoma.
In addition you may be asked for permission for some of your lymphoma sample to be retained for future laboratory research studies.
MCL biobank is appropriate for patients with newly diagnosed mantle cell lymphoma (MCL).
We are asking people with a recent diagnosis of MCL, prior to treatment, to donate a sample of blood and a sample of saliva. We would also like to examine part of the tissue biopsy sample that was taken to diagnose your MCL.
Once the samples have been taken, you won't be asked to do anything further. The rest of the study involves collecting information from your hospital notes about your MCL and any treatment you may have. Your normal visits to hospital for monitoring and treating your MCL will continue.
The purpose of this study is to find out differences between indolent and aggressive forms of MCL.
The information provided, as a result of your participation, may help to improve the treatment of people with MCL in the future.
PTCL Biobank is appropriate for patients with Peripheral T-cell Lymphoma (PTCL) who are either newly diagnosed or have already received treatment but it has come back.
We are asking people with newly presenting or relapsed/refractory PTCL to donate samples of blood and saliva. We would also like to take part of a stored tissue biopsy sample which you will have had taken earlier to confirm your diagnosis of PTCL. You will only need to provide one saliva sample but during the course of your treatment and subsequent follow-up visits to the hospital we will collect blood samples at intervals of between three and six months (depending on your treatment and follow up arrangements).
Your saliva and blood samples will be sent to the biobank at the University of Liverpool. At the biobank, your blood sample will be processed so that it can be used for a number of tests. Part of it will be frozen and placed in long term secure storage so that it can be looked at in the future.
The rest of the study involves collecting information from your hospital notes about your PTCL and any treatment you may have.
The information provided from your samples and hospital notes may help to improve the treatment of people with PTCL in the future
If you would like to be involved, email us at: email@example.com for more information.